Holen Sie sich die Stockscreener-App
22.94
9.03%
1.90
Vorhandelsmarkt:
23.63
0.69
+3.01%
Schlusskurs vom Vortag:
$21.04
Offen:
$21.18
24-Stunden-Volumen:
178.51K
Relative Volume:
0.80
Marktkapitalisierung:
$821.81M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+20.17%
1M Leistung:
-14.78%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$21.13
$23.22
1-Wochen-Bereich:
$19.20
$23.22
52-Wochen-Spanne:
$18.69
$32.75
Ceribell Inc Stock (CBLL) Company Profile
Firmenname
Ceribell Inc
Sektor
Branche
Telefon
(800) 436-0826
Adresse
360 N. PASTORIA AVENUE, SUNNYVALE
Vergleichen Sie CBLL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CBLL
Ceribell Inc
|
22.94 | 821.81M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
116.79 | 201.01B | 41.22B | 5.77B | 6.49B | 3.29 |
|
SYK
Stryker Corp
|
395.85 | 150.90B | 21.97B | 3.59B | 3.21B | 9.33 |
|
BSX
Boston Scientific Corp
|
100.91 | 148.72B | 15.91B | 1.79B | 1.89B | 1.21 |
|
MDT
Medtronic Plc
|
88.38 | 113.33B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
69.97 | 41.27B | 6.60B | 4.16B | 490.10M | 6.93 |
Ceribell Inc Stock (CBLL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-11-05 | Eingeleitet | BofA Securities | Buy |
| 2024-11-05 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-05 | Eingeleitet | JP Morgan | Overweight |
| 2024-11-05 | Eingeleitet | TD Cowen | Buy |
| 2024-11-05 | Eingeleitet | William Blair | Outperform |
Ceribell Inc Aktie (CBLL) Neueste Nachrichten
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus Price Target from Analysts - Defense World
CeriBell (NASDAQ:CBLL) Given Average Rating of "Buy" by Analysts - MarketBeat
Ceribell Expands its Executive Management Team by Two - MPO-mag
CeriBell (NASDAQ:CBLL) Hits New 52-Week LowTime to Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Shares Down 9.2%Should You Sell? - MarketBeat
CeriBell (NASDAQ:CBLL) Trading Down 3.3%What's Next? - MarketBeat
Contrasting CeriBell (NASDAQ:CBLL) & Cutera (NASDAQ:CUTR) - Defense World
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CeriBell (NASDAQ:CBLL) Receives $32.60 Consensus PT from Analysts - Defense World
Head to Head Contrast: CeriBell (NASDAQ:CBLL) & Vaso (OTCMKTS:VASO) - Defense World
Ceribell Receives Authority to Operate from the U.S. Department of Veterans Affairs - Marketscreener.com
CeriBell (NASDAQ:CBLL) Shares Down 2.6%Here's Why - MarketBeat
CeriBell (NASDAQ:CBLL) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Ceribell CEO to Present at J.P. Morgan Healthcare Conference 2025: Medical Tech Innovation in Focus - StockTitan
CeriBell, Inc. Announces Closing of Upsized Initial Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - The Eastern Progress Online
CeriBell (NASDAQ:CBLL) Price Target Raised to $33.00 at Canaccord Genuity Group - Defense World
CeriBell (NASDAQ:CBLL) Given New $36.00 Price Target at TD Cowen - Defense World
Ceribell shares PT raised by analyst to reflect higher EV/sales momentum - Investing.com UK
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
Top 145+ startups in Smart EEG Devices in Nov, 2024 - Tracxn
CeriBell: Healthcare Technology Stock With A Promising Growth Outlook (NASDAQ:CBLL) - Seeking Alpha
Ceribell appoints Rodenbush as CPO, Price as SVP of Marketing - TipRanks
Ceribell Appoints Kristie Rodenbush as Chief People Officer and Brian Price as Senior Vice President of Marketing - The Manila Times
Ceribell Strengthens Leadership Team with Key AI Medical Device Executives | CBLL Stock News - StockTitan
Meet the biophysicist whose seizure-detection company is using AI to get a better read on people's brains - Fast Company
FY2024 EPS Estimates for CeriBell Reduced by William Blair - MarketBeat
William Blair Estimates CeriBell's Q1 Earnings (NASDAQ:CBLL) - MarketBeat
Ceribell revenue increases 48% to USD 17.2M in Q3 2024 - Medical Buyer
Ceribell, Inc. Reports Strong Q3 2024 Growth - Yahoo Finance
Ceribell price target raised to $31 from $30 at Canaccord - TipRanks
CeriBell (NASDAQ:CBLL) Price Target Raised to $31.00 at Canaccord Genuity Group - MarketBeat
CeriBell’s Quiet Period To End on November 20th (NASDAQ:CBLL) - Defense World
CeriBell's (NASDAQ:CBLL) Quiet Period To End on November 20th - MarketBeat
Ceribell Reports Third Quarter 2024 Financial Results - GlobeNewswire
CeriBell, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Ceribell Secures VA Authorization, Expands AI-Powered EEG Tech to Veterans Hospitals | CBLL Stock News - StockTitan
Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum - The Manila Times
Q3 Earnings Estimate for CeriBell Issued By William Blair - Defense World
Brokerages Set CeriBell (NASDAQ:CBLL) PT at $31.00 - Defense World
Ceribell started with bullish ratings by J.P. Morgan, Canaccord - MSN
FMR LLC Acquires New Stake in CeriBell Inc - GuruFocus.com
Ceribell initiated with a Buy at BofA on ‘differentiated AI algorithm’ - Yahoo Finance
Ceribell stock a buy as JPMorgan highlights disruptive tech in $3B seizure market - Investing.com Australia
Ceribell initiated with an Overweight at JPMorgan - MSN
Ceribell started with bullish ratings by J.P. Morgan, Canaccord (NASDAQ:CBLL) - Seeking Alpha
Finanzdaten der Ceribell Inc-Aktie (CBLL)
Es liegen keine Finanzdaten für Ceribell Inc (CBLL) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
3.55%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):